News und Analysen

Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the

Bayer today announced that its MEDRAD^® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast

Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary

Regulatory News:

ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its

A recent study conducted by Humana Healthcare Research, with strategic input from researchers at the University of Pennsylvania, reveals key insights into how Medicare Advantage beneficiaries

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved HYRNUO^® (sevabertinib), an oral, reversible, tyrosine kinase inhibitor (TKI), for the treatment of adult patients